APA (7th ed.) Citation

Wang, L., Ma, S., Su, H., Nie, D., & Wang, L. The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment. Springer.

Chicago Style (17th ed.) Citation

Wang, Liangliang, Shanshan Ma, Huiwen Su, Dandan Nie, and Lihua Wang. The Molecular Mechanism of Gemcitabine in Inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 Signaling Pathway for Ovarian Cancer Treatment. Springer.

MLA (9th ed.) Citation

Wang, Liangliang, et al. The Molecular Mechanism of Gemcitabine in Inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 Signaling Pathway for Ovarian Cancer Treatment. Springer.